Published in

BioMed Central, Arthritis Research and Therapy, 3(13), p. 114

DOI: 10.1186/ar3346

Links

Tools

Export citation

Search in Google Scholar

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed

Journal article published in 2011 by Christopher P. Denton, Jerome Avouac, Frank Behrens, Daniel E. Furst, Ivan Foeldvari, Marc Humbert, Doerte Huscher, Otylia Kowal-Bielecka, Marco Matucci-Cerinic, Peter Nash ORCID, Christian F. Opitz, David Pittrow, Lewis J. Rubin, James R. Seibold, Oliver Distler
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Pulmonary arterial hypertension (PAH) is a serious complication of systemic sclerosis (SSc). In clinical trials PAH-SSc has been grouped with other forms, including idiopathic PAH. The primary endpoint for most pivotal studies was improvement in exercise capacity. However, composite clinical endpoints that better reflect long-term outcome may be more meaningful. We discuss potential endpoints and consider why the same measures may not be appropriate for both idiopathic PAH and PAH-SSc due to inherent differences in clinical outcome and management strategies of these two forms of PAH. Failure to take this into account may compromise progress in managing PAH in SSc.